<DOC>
	<DOCNO>NCT03105336</DOCNO>
	<brief_summary>This study enroll approximately 50 adult subject relapse refractory ( r/r ) iNHL infuse study treatment , axicabtagene ciloleucel , see disease responds experimental product product safe . Axicabtagene ciloleucel make subject white blood cell genetically modify grown fight cancer . An objective response rate 70 % target .</brief_summary>
	<brief_title>A Phase 2 Multicenter Study Axicabtagene Ciloleucel Subjects With Relapsed/Refractory Indolent Non-Hodgkin Lymphoma ( iNHL )</brief_title>
	<detailed_description>This study enroll approximately 50 adult subject relapse refractory ( r/r ) iNHL infuse study treatment , axicabtagene ciloleucel , see disease responds experimental product product safe . Axicabtagene ciloleucel make subject white blood cell genetically modify grown fight cancer . An objective response rate 70 % target . All enrolled subject screen eligibility undergo leukapheresis collect white blood cell manufacture . In preparation infusion axicabtagene ciloleucel , subject undergo condition chemotherapy cyclophosphamide fludarabine 3 day help study treatment effective . After product manufacture conditioning chemotherapy period complete , subject infuse axicabtagene ciloleucel monitor hospital minimum 7 day . Subjects follow study doctor continue monitor safety effectiveness study treatment approximately 3 month receive treatment follow safety additional 3 Â½ year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<criteria>1 ) Subject [ follicular lymphoma relapse within 24 month first diagnosis treatment combination chemoimmunotherapy ] ( e.g . Rbendamustine , RCHOP ) OR Progression iNHL within 6 month completion second later line therapy contain antiCD20 antibody alkylating agent OR Progression iNHL point follow autologous transplantation . 2 ) Subject [ measurable disease ] . 3 ) Subject know presence history CNS involvement lymphoma . 4 ) If subject conventional systemic therapy systemic inhibitory/stimulatory immune checkpoint therapy , subject able stop conventional therapy 2 week 5 halflives , whichever short , immune checkpoint therapy 3 halflives prior plan leukapheresis . 5 ) Subject ECOG performance status 01 adequate renal , hepatic , pulmonary , cardiac function 6 ) Subject pregnant breastfeeding ( female subject ) willing use birth control time consent 6 month follow CAR T cell infusion ( male female subject ) .B24 1 ) Transformed FL 2 ) Small lymphocytic lymphoma 3 ) Histological Grade 3b FL 4 ) Subject undergone autologous transplant within 6 week plan leukapheresis undergone allogeneic transplant . 5 ) Subject evidence involvement heart lymphoma requirement urgent therapy due ongoing impend oncologic emergency ( e.g . mass effect , tumor lysis syndrome , etc . )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
</DOC>